Industry TrendsBrand Founders3 min read5 January 2026

Peptides Are Having a Moment. Here's What Beauty Brands Actually Need to Know.

Peptide-led skincare is projected to hit $8.2bn by 2028. But most brands are getting the formulation story wrong.

SL
Sophie Lansbury

Beauty 2.0 Founder - 20 years in the beauty industry

Pick one hero peptide, explain exactly what it does for skin, and own that story - multi-peptide complexity is a marketing crutch, not a differentiator.

Key takeaway

In brief
What beauty brands actually need to know about the peptide boom - formulation strategy, consumer education, and how to stand out in a crowded market.
Who this is for
Brand Founders
Main takeaway
Pick one hero peptide, explain exactly what it does for skin, and own that story - multi-peptide complexity is a marketing crutch, not a differentiator.
What to do next
Audit your current peptide narrative and test whether a customer can explain your hero ingredient after one page visit.

The peptide boom is real - and messy

Every other brand launching in 2026 seems to have peptides as a hero ingredient. Matrixyl, Argireline, copper peptides, signal peptides - the language is everywhere. And for good reason: consumer search volume for "peptide skincare" is up 340% year-on-year.

But here's what most brands are getting wrong: they're treating peptides like a checkbox. Throw in three peptides, slap "multi-peptide complex" on the label, and call it innovation.

That's not innovation. That's ingredient stuffing. And consumers are getting smarter.

What consumers actually want

The shift we're seeing across our client base is this: consumers don't want more ingredients. They want clearer stories about fewer ingredients.

They want to understand what one peptide does and why it matters for their specific concern. Not a laundry list of five peptides with no explanation of how they work together.

The brands winning right now are the ones that:

  • Pick one hero peptide and build the entire product narrative around it
  • Explain the mechanism of action in plain language (not in clinical jargon)
  • Show before-and-after evidence or clinical trial results
  • Position the peptide within a routine context, not in isolation

The formulation challenge brands underestimate

Peptide stability is genuinely difficult. Copper peptides degrade in the wrong pH environment. Signal peptides need specific delivery systems to actually penetrate. Most contract manufacturers will happily formulate a "peptide serum" at concentrations too low to have any meaningful effect, and you'll never know unless you ask the right questions.

Questions to ask your formulator:

  • What is the minimum effective concentration for this peptide, and are we at or above it?
  • What is the stability profile across our target shelf life?
  • How does this peptide interact with the other active ingredients in the formula?
  • Is there clinical evidence for this specific peptide at this concentration?

If your formulator can't answer these clearly, that's a red flag.

The regulatory angle

Claims around peptides are getting tighter. The EU Commission has been increasingly scrutinising "botox-like" and "anti-wrinkle" claims linked to peptide products. If you're positioning a topical peptide as a replacement for injectables - even implicitly - you need robust evidence or you're exposed.

Safe positioning: focus on skin texture, firmness, and hydration benefits. Avoid any comparison to medical procedures, even casually in marketing copy.

What this means for your brand

If you're formulating with peptides, be honest with yourself about whether you're leading with science or with buzzwords. The market is saturated enough that "contains peptides" is no longer a differentiator. The differentiator is clarity: one peptide, one story, one proof point.

The brands that will still be winning in 2027 are the ones investing in the science now, not just the label claims.

Share
SL

Sophie Lansbury

Founder of Beauty 2.0. Nearly 20 years in beauty — from counter to boardroom, indie launches to global houses. Writes about the operational reality of growing beauty brands.

About Sophie
“

The brands winning with peptides aren't the ones with the longest INCI list. They're the ones telling the clearest story about one hero peptide and what it does.

Ti è stato utile?

Related posts

THE SUPPLY CHAIN YOU CANNOT SEESUPPLIER ASUPPLIER BYOUR CONTRACT MANUFACTURERYOUR BRANDPRICE UPMOQ UPREFORMULATE?NO LABELON THE CAUSE
Industry TrendsBrand FoundersEU5 min read

BASF Has Bid €10.3bn for Evonik. Two of the Biggest Suppliers of Your Formula's Ingredients May Become One.

Personal Care Insights reported on 29 September that BASF has confirmed exploratory talks to acquire Evonik, with an opening offer of €22.15 per share valuing the equity at €10.3bn and the enterprise at €14.2bn, which Evonik reportedly rejected as too low. Both supply actives, emollients and surfactants that end up in small brands' formulas through contract manufacturers. Consolidation upstream reaches you late, indirectly, and without warning.

5 Oct 2026Read →
WHAT GETS YOU THE SHELFRETAILER BEAUTY FIXTUREPRODUCTBEAUTY BRANDPRODUCTLIFESTYLE BRAND + ITS AUDIENCEFOOTFALL WINS TIES
Industry TrendsBrand FoundersUK5 min read

Sweaty Betty and Bella Freud Both Launched Beauty Through Boots This Month. Neither Is a Beauty Brand.

Global Cosmetics News reported Sweaty Betty's Beauty and Wellness Collection on 21 September and Bella Freud's Glamorama collection on 25 September, both launching exclusively through Boots. Two adjacent-category brands entering beauty through the same retailer in the same week is a pattern rather than a coincidence, and it says something uncomfortable about what a retailer values when choosing who to back.

27 Sept 2026Read →
MINORITY 2022, MAJORITY 202620222026MINORITY STAKEMAJORITY STAKEFOUR YEARSDISTRIBUTION, NOT JUST CASHFOUNDER KEEPS EQUITY AND THE CHAIR
Industry TrendsBrand FoundersEU5 min read

Caudalie Took a Minority Stake in Talm in 2022 and the Majority in 2026. The Founder Kept Equity and Stayed CEO.

Global Cosmetics News reported on 15 September that Caudalie has acquired a majority stake in French skincare brand Talm, its first ever acquisition of another brand. Founder Kenza Keller retains a minority stake and continues as chief executive. Talm has 12 products across roughly 60 doors in 12 countries. The four-year path from minority investment to majority is a deal shape that suits brands at exactly this size, and most founders have never considered it.

20 Sept 2026Read →